Following the 6 April meeting of the NICE Technology Appraisal Committee to discuss lenalidomide for treating multiple myeloma after 1 prior treatment with bortezomib the Committee have decided to request additional evidence from the company.
No Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) will be issued until after the Committee have discussed this appraisal again. The date for the next Committee meeting has not been confirmed.